Open your eyes, the new xoma is BpEye !!!
Raptiva is history, even one billion in sales (tough call)hardly justify current price, everything is going to Dna, xoma knows that is why they are rushing to pay the shares Dna owns, otherwise why not let Dna keep and dump shares, dilution is mandated because Dna wants to be paid for their investment in Raptiva and $80 millions is a better return than coming sales for Dna. Do you think that Biogen invented the tough reimbursement enviroment with Amevive! think harder, xomaDna will find more of the same (oh, no way , only evil Biogen with Amevive poison go throug that), no monitoring for platelets and flare hospitalizations are Amevive problems, and arthritis, and infections, and lymphoproliferative disorders (only 2) HISTORY !!!
Time for xoma to produce another 50 million shares, they should fund BpEye NOW, deal now with Sgp, Bmy, Abt, BOL, even Bioevilgen if they bring the DOLLARS to tell the Joslin FULL PEDAL AHEAD.
DNA-Lucentis in phase III
Pfizer/Eyetech-Macugen in phase III
Lilly's Ruboxistaurin (BpEye complements this Lilly effort)in phase III
Even a tiny BB company (with a Mexican trial!) is moving ahead with clinicals in the US, soon to go to phase I
xoma is BEHIND in preclinicals...time to push to the CLINIC
BpEye is the future of xoma!!!
Send the Mlnm drugs back to mlnm. Money for the Joslin!!! |
